Group 1 - The medical beauty sector experienced a decline of 2.68% on November 4, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] - Major stocks in the medical beauty sector showed varied performance, with *ST Meigu closing at 3.74 (+0.27%), Huaxi Biological at 52.05 (-2.01%), Aimeike at 151.92 (-3.46%), and Jinbo Biological at 243.02 (-4.84%) [1] Group 2 - The medical beauty sector saw a net outflow of 101 million yuan from institutional investors, while retail investors had a net inflow of 79.55 million yuan [1] - The trading volume and turnover for key stocks included *ST Meigu with 140,600 shares traded and a turnover of 53.3 million yuan, Huaxi Biological with 29,200 shares and 153 million yuan, Aimeike with 43,500 shares and 669 million yuan, and Jinbo Biological with 15,400 shares and 378 million yuan [1]

Market Overview - The medical beauty sector experienced a decline of 1.4% on November 3, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Individual Stock Performance - *ST Meigu (000615) closed at 3.73, with an increase of 4.19% and a trading volume of 150,000 shares, totaling a transaction value of 5.5589 million yuan [1] - Jinbo Biological (920982) closed at 255.37, up 1.63%, with a trading volume of 15,700 shares and a transaction value of 403 million yuan [1] - Huaxi Biological (688363) closed at 53.12, down 1.61%, with a trading volume of 29,400 shares and a transaction value of 156 million yuan [1] - Ai Meike (300896) closed at 157.37, down 1.70%, with a trading volume of 33,400 shares and a transaction value of 5.271 billion yuan [1] Capital Flow Analysis - The medical beauty sector saw a net inflow of 2.7789 million yuan from main funds, while retail investors experienced a net outflow of 3.33256 million yuan [1] - Main funds for *ST Meigu showed a net inflow of 6.9892 million yuan, while retail investors had a net outflow of 652.99 thousand yuan [2] - Ai Meike had a net inflow of 1.4812 million yuan from main funds, but a net outflow of 1.89798 million yuan from retail investors [2] - Huaxi Biological experienced a net outflow of 5.6915 million yuan from main funds and a net outflow of 781.58 thousand yuan from retail investors [2]

Core Viewpoint - The medical beauty sector experienced a slight increase of 0.81% on October 31, with Jinbo Biological leading the gains, while the overall market indices saw declines [1]. Group 1: Market Performance - On October 31, the Shanghai Composite Index closed at 3954.79, down 0.81%, and the Shenzhen Component Index closed at 13378.21, down 1.14% [1]. - Jinbo Biological's stock price rose by 2.35% to 251.28, with a trading volume of 16,800 hands and a transaction value of 421 million yuan [1]. - Other notable stocks in the medical beauty sector included *ST Meigu, which increased by 1.42% to 3.58, and Huaxi Biological, which rose by 0.82% to 66.65 [1]. Group 2: Capital Flow - The medical beauty sector saw a net inflow of 5.8151 million yuan from institutional investors, while retail investors experienced a net outflow of 7.1663 million yuan [2]. - The sector also recorded a net inflow of 1.3512 million yuan from speculative funds [2].

Core Viewpoint - The A-share market shows mixed performance with the Shanghai Composite Index down by 0.40%, while the Shenzhen Component Index and the ChiNext Index show slight increases of 0.09% and a decrease of 0.09% respectively. The Kexin Pharmaceutical ETF fund has risen by 2.36% [1] Group 1: Market Performance - As of 9:56, the Shanghai Composite Index decreased by 0.40% [1] - The Shenzhen Component Index increased by 0.09% [1] - The ChiNext Index decreased by 0.09% [1] - The Kexin Pharmaceutical ETF fund (588130) rose by 2.36%, with a latest price of 1.173 yuan and a turnover rate of 6.15% [1] Group 2: Stock Movements - Among the constituent stocks, three major gainers include: - Sanofi's stock increased by 15.95% [1] - Borui Pharmaceutical rose by 10.10% [1] - Microchip Biotech increased by 6.94% [1] - Major decliners include: - Shenzhou Cell decreased by 5.68% [1] - Haoyuan Pharmaceutical fell by 3.93% [1] - Baifen Medical dropped by 1.26% [1] Group 3: Clinical Trials and Policy Changes - On October 30, Pfizer registered two global Phase III clinical trials for the PD-1/VEGF dual antibody PF-08634404 (SSGJ-707) on Clinicaltrials.gov, targeting advanced non-small cell lung cancer and metastatic colorectal cancer in combination with chemotherapy [1] - The 2025 National Medical Insurance negotiation has officially started, introducing a "commercial insurance innovative drug catalog" mechanism, which aims to alleviate the payment pressure of high-value innovative drugs through commercial insurance channels [1] Group 4: Industry Composition - The Kexin Pharmaceutical ETF fund tracks an index with a weight distribution concentrated in: - Medical Devices (36.76%) - Chemical Pharmaceuticals (36.62%) - Biological Products (18.84%) - Medical Services (4.32%) - Medical Aesthetics (2.03%) [2]

Core Viewpoint - Langzi Co., Ltd. has shown a significant increase in stock price, reaching 19.94 CNY per share with a market capitalization of 8.822 billion CNY, indicating strong investor interest and trading activity [1]. Company Overview - Langzi Co., Ltd. was established on November 9, 2006, and went public on August 30, 2011. The company is based in Chaoyang District, Beijing, and specializes in the design, production, and sales of branded women's clothing [1]. - The main revenue composition of Langzi includes: non-surgical medical beauty (41.59%), women's skirts (11.34%), women's tops (11.22%), children's clothing (10.90%), women's outerwear (9.55%), surgical medical beauty (6.21%), children's products (4.70%), women's pants (3.31%), and others (1.18%) [1]. Shareholder Information - Among the top ten circulating shareholders of Langzi, a fund under Southern Fund holds a position. The Southern CSI 1000 ETF (512100) reduced its holdings by 24,300 shares in the third quarter, now holding 2.021 million shares, which accounts for 0.79% of the circulating shares [2]. - The Southern CSI 1000 ETF has a total scale of 76.63 billion CNY and has achieved a year-to-date return of 27.12%, ranking 2130 out of 4216 in its category [2]. Fund Management - The fund manager of Southern CSI 1000 ETF is Cui Lei, who has been in the position for 6 years and 360 days. The total asset scale under management is 122.76 billion CNY, with the best fund return during the tenure being 182.39% and the worst being -15.93% [3].

Core Insights - The medical beauty market in Changsha has experienced significant growth, with the market size expected to reach 80 billion yuan by 2025, up from less than 3 billion yuan in 2009 and over 50 billion yuan in 2020 [1][2][5] - The industry is currently facing a dichotomy, with a booming market contrasted by the closure of many medical beauty institutions and financial struggles among operators [1][12] - The rise of public hospitals offering medical beauty services has led to a shift in market dynamics, with public institutions gaining market share at the expense of private clinics [12][18] Market Growth and Structure - The medical beauty industry in Changsha began with public hospitals in the 1990s, but the real expansion occurred with the emergence of private medical institutions in the early 2000s [2][3] - By 2020, the number of registered medical beauty institutions in Changsha peaked at around 410, but this number has since decreased to approximately 200 due to market challenges [5][13] - Currently, there are about 370 registered medical beauty hospitals in Changsha, including 17 large specialized hospitals, with over 20,000 practitioners in the city [5][12] Industry Challenges - The private medical beauty sector has seen a slowdown in growth, while public hospitals have been expanding their medical beauty departments [12][18] - Issues such as "black medical beauty" practices, which include unlicensed operations and misleading advertising, have damaged the reputation of private institutions [19][20][23] - Consumer complaints have increased, focusing on poor service outcomes, refund issues, and deceptive marketing practices [20][21][22] Regulatory and Self-Regulatory Measures - The Changsha Medical Beauty Association was established to promote industry standards and combat illegal practices, introducing initiatives like the "Safety Commitment Guarantee Plan" to protect consumer rights [24][25] - The government is enhancing regulatory oversight, with regular compliance training and inspections of medical beauty institutions to ensure adherence to legal standards [26] - The industry is undergoing a restructuring phase, with predictions that only well-established brands and specialized institutions will survive, while those lacking competitive advantages will be eliminated [27]

Core Viewpoint - Langzi Co., Ltd. is a well-known enterprise in the domestic fashion consumption sector, with strong brand influence and resource reserves in the medical beauty industry [1] Group 1: Business Performance - In Q3 2025, Langzi achieved a revenue of 4.328 billion yuan, ranking 5th among 38 companies in the industry, with the top company, Hailan Home, generating 15.599 billion yuan [2] - The net profit for the same period was 1.019 billion yuan, ranking 3rd in the industry, with the top company, Youngor, reporting 2.334 billion yuan [2] - The main business composition includes non-surgical medical beauty at 1.16 billion yuan (41.59% of revenue) and women's clothing at 316 million yuan (11.34% of revenue) [2] Group 2: Financial Ratios - As of Q3 2025, Langzi's debt-to-asset ratio was 52.95%, down from 54.17% year-on-year, which is higher than the industry average of 38.41% [3] - The gross profit margin for the same period was 59.35%, up from 58.92% year-on-year, exceeding the industry average of 44.68% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 10.93% to 51,400, while the average number of circulating A-shares held per shareholder increased by 12.27% to 4,957.27 [5] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 1000 ETF, with notable changes in their holdings [5] Group 4: Management Compensation - The chairman, Shen Dongri, received a salary of 899,600 yuan in 2024, a slight decrease from 900,000 yuan in 2023 [4] - The general manager, Shen Jinhua, also received a salary of 899,600 yuan in 2024, reflecting the same decrease [4] Group 5: Strategic Developments - The company has been actively expanding its medical beauty segment, acquiring Chongqing Milan Baiyu Time Aesthetic Hospital, and has established seven medical beauty acquisition funds with a total scale of 2.837 billion yuan [6] - The revenue from the light medical beauty chain brands "Jingfu Medical Beauty" and "Hancheng Medical Beauty" grew by 6.0% and 9.5%, respectively, in the first half of 2025 [6]

Core Insights - The medical beauty sector experienced a decline of 0.81% on October 30, with Jinbo Biological leading the drop at 7.07% [1] - The Shanghai Composite Index closed at 3986.9, down 0.73%, while the Shenzhen Component Index closed at 13532.13, down 1.16% [1] Medical Beauty Sector Performance - Huaxi Biological closed at 53.55, down 0.70%, with a trading volume of 30,900 shares and a transaction value of 166 million [1] - *ST Meigu closed at 3.53, down 0.84%, with a trading volume of 71,000 shares and a transaction value of 25.09 million [1] - Aimeike closed at 158.89, down 0.89%, with a trading volume of 30,100 shares and a transaction value of 47.9 million [1] - Jinbo Biological closed at 245.50, down 7.07%, with a trading volume of 29,300 shares and a transaction value of 733 million [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 2.1553 million from main funds, while retail funds experienced a net outflow of 3.2717 million [1] - Speculative funds had a net inflow of 5.4269 million [1] Individual Stock Capital Flow - Aimeike had a net outflow of 15.355 million, down 3.21%, with a net inflow of 21.139 million, down 0.44% [2] - *ST Meigu experienced a net outflow of 5.6326 million, down 22.45%, with a net inflow of 4.3275 million, up 17.25% [2] - Huaxi Biological had a net outflow of 13.9915 million, down 8.41%, with a net inflow of 16.4544 million, up 9.89% [2]

Investment Rating - The investment rating for the company is "Outperform the Market" [3][5][12] Core Views - The company's overall performance in Q3 2025 was under pressure, with revenue of 566 million yuan, a year-on-year decrease of 21.27%, and a net profit attributable to shareholders of 304 million yuan, down 34.61% year-on-year. The first three quarters saw a revenue decline of 21.49% and a net profit drop of 31.05% [2][3] - The decline in performance is attributed to ongoing consumer spending pressures and intensified competition in the medical beauty industry. Additionally, the company is in a transitional phase with its product line, as traditional medical beauty products are experiencing weakened demand. Future focus will be on the development of new medical beauty products such as botulinum toxin and weight loss solutions [2][3] - The gross profit margin for Q3 2025 was 93.19%, a decrease of 1.36 percentage points year-on-year, influenced by changes in product structure and increased industry competition. The company has maintained a commitment to R&D, with R&D expenses rising by 5.72% year-on-year to 14.3% of revenue [2][3] - The company has adjusted its net profit forecasts for 2025-2027 to 1.564 billion, 1.794 billion, and 2.099 billion yuan, respectively, reflecting a decrease from previous estimates. The corresponding price-to-earnings ratios are projected to be 31.6, 27.5, and 23.5 times [3][12] Financial Summary - For 2025, the company is expected to generate revenue of 2.598 billion yuan, a decrease of 14.13% year-on-year, with a net profit of 1.564 billion yuan, down 20.10% year-on-year. The earnings per share are projected to be 5.18 yuan [4][14] - The company's EBIT margin is forecasted to be 68.37% for 2025, with a return on equity (ROE) of 17.86% [4][14] - The company’s cash flow from operations for the first three quarters was 1.073 billion yuan, a decrease of 30.12% year-on-year, primarily due to the decline in net profit and changes in working capital [2][3]

Investment Rating - The investment rating for the company is "Buy" with a maintained rating for the next six months [6][17]. Core Views - The company experienced a temporary pressure on performance in Q3 2025, with revenue of 1.865 billion yuan, down 21.49% year-on-year, and a net profit of 1.093 billion yuan, down 31.05% year-on-year. The outlook remains positive due to pipeline developments and overseas expansion opportunities [1][5]. - The company has a strong R&D capability and is entering the cosmetic raw materials sector, with several products in various stages of approval and clinical trials, which is expected to enhance growth potential [3]. - The acquisition of Korean company REGEN is a strategic move to enhance international presence, with products already gaining significant market share in various regions, indicating a strong potential for future growth [4]. Financial Performance Summary - For Q1-Q3 2025, the gross margin was 93.36%, down 1.44 percentage points year-on-year, and the net profit margin was 58.62%, down 8.12 percentage points year-on-year. The sales expense ratio increased to 12.39%, while the R&D expense ratio rose to 12.73% [2]. - The company forecasts revenues of 2.853 billion yuan for 2025, down from previous estimates, with net profits expected to be 1.604 billion yuan, reflecting a downward adjustment in profit expectations due to industry slowdown and increased competition [5][11]. Future Outlook - The company is expected to see revenue growth in the coming years, with projections of 2.853 billion yuan in 2025, 3.333 billion yuan in 2026, and 3.798 billion yuan in 2027, indicating a recovery trajectory post-2025 [5][10]. - The company maintains a leading position in the medical beauty sector, with ongoing R&D and strategic acquisitions expected to drive future growth [5][4].